EC
AMPH icon

EntryPoint Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

EntryPoint Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,498
Closed -$246K – 606
2025
Q1 		$246K Sell
8,498
-5,160
-38% -$165K 0.11% 437
2024
Q4 		$507K Buy
13,658
+4,348
+47% +$199K 0.21% 101
2024
Q3 		$452K Buy
9,310
+3,412
+58% +$150K 0.26% 80
2024
Q2 		$236K Buy
5,898
+2,291
+64% +$94.9K 0.11% 315
2024
Q1 		$158K Buy
3,607
+2,859
+382% +$148K 0.14% 197
2023
Q4 		$46.3K Buy
+748
New +$39.3K 0.04% 762

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

EntryPoint Capital's AMPH Position: Q2 2025 in Review

EntryPoint Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 8,498 shares — an estimated $246K sold.

EntryPoint Capital first reported a position in AMPH in Q4 2023 and held it in 6 quarters. The position peaked at $507K in Q4 2024. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • EntryPoint Capital reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 8,498 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $246K.
  • EntryPoint Capital first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • EntryPoint Capital's Amphastar Pharmaceuticals position peaked at $507K in Q4 2024.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.